BRAF mutation testing in clinical practice

References

• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell6(4), 313–319 (2004).
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol.26(35), 5705–5712 (2008).
   PubMed Web of Science ®Google Scholar
• Yokota T, Ura T, Shibata N et al.BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br. J. Cancer104(5), 856–862 (2011).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med.363(9), 809–819 (2010).
   PubMed Web of Science ®Google Scholar
• Nikiforov YE. Molecular analysis of thyroid tumors. Mod. Pathol.24(Suppl. 2), S34–S43 (2011).
   Google Scholar
• Takezawa K, Okamoto I, Yonesaka K et al. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res.69(16), 6515–6521 (2009).
   PubMedGoogle Scholar
• Singer G, Oldt R 3rd, Cohen Y et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl Cancer Inst.95(6), 484–486 (2003).
   PubMed Web of Science ®Google Scholar
• Tiacci E, Trifonov V, Schiavoni G et al.BRAF mutations in hairy-cell leukemia. N. Engl. J. Med.364(24), 2305–2315 (2011).
   PubMed Web of Science ®Google Scholar
• Lupi C, Giannini R, Ugolini C et al. Association of BRAFV600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab.92(11), 4085–4090 (2007).
   PubMed Web of Science ®Google Scholar
• Barnier JV, Papin C, Eychene A, Lecoq O, Calothy G. The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J. Biol. Chem.270(40), 23381–23389 (1995).
   PubMed Web of Science ®Google Scholar
• Valluet A, Hmitou I, Davis S et al.B-raf alternative splicing is dispensable for development but required for learning and memory associated with the hippocampus in the adult mouse. PLoS One5(12), e15272 (2010).
   Google Scholar
• Kolch W. Meaningful relationships: the regulation of the RAS/Raf/MEK/ERK pathway by protein interactions. Biochem. J.351(Pt 2), 289–305 (2000).
   PubMed Web of Science ®Google Scholar
• Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell20(6), 963–969 (2005).
   PubMed Web of Science ®Google Scholar
• Hmitou I, Druillennec S, Valluet A, Peyssonnaux C, Eychene A. Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms. Mol. Cell Biol.27(1), 31–43 (2007).
   PubMed Web of Science ®Google Scholar
• Huser M, Luckett J, Chiloeches A et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J.20(8), 1940–1951 (2001).
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell116(6), 855–867 (2004).
   PubMed Web of Science ®Google Scholar
• Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J.18(8), 2137–2148 (1999).
   PubMed Web of Science ®Google Scholar
• Heidorn SJ, Milagre C, Whittaker S et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell140(2), 209–221 (2010).
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer VC, Karasarides M, Hayward R, Marais R. Tumor necrosis factor-α blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res.67(1), 122–129 (2007).
   PubMed Web of Science ®Google Scholar
• Champion KJ, Bunag C, Estep AL et al. Germline mutation in BRAF codon 600 is compatible with human development: de novop.V600G mutation identified in a patient with CFC syndrome. Clin. Genet.79(5), 468–474 (2011).
   PubMedGoogle Scholar
• Ritt DA, Monson DM, Specht SI, Morrison DK. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell Biol.30(3), 806–819 (2010).
   PubMed Web of Science ®Google Scholar
• Adeniran AJ, Theoharis C, Hui P et al. Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study. Thyroid21(7), 717–723 (2011).
   PubMed Web of Science ®Google Scholar
• Hay R, Macrae E, Barber D, Khalil M, Demetrick DJ. BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products. Arch. Pathol. Lab Med.131(9), 1361–1367 (2007).
   PubMed Web of Science ®Google Scholar
• Rowe LR, Bentz BG, Bentz JS. Detection of BRAFV600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J. Clin. Pathol.60(11), 1211–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Shackelford W, Deng S, Murayama K, Wang J. A new technology for mutation detection. Ann. NY Acad. Sci.1022, 257–262 (2004).
   PubMed Web of Science ®Google Scholar
• Arruda VR, Von Zuben PM, Annichino-Bizzachi JM, Costa FF. Rapid detection of factor V Leiden (FVQ506) by non-radioactive single strand conformation polymorphism (SSCP). Sangre41(5), 379–381 (1996).
   PubMedGoogle Scholar
• Dillon D, Zheng K, Costa J. Rapid, efficient genotyping of clinical tumor samples by laser-capture microdissection/PCR/SSCP. Expert Mol. Pathol.70(3), 195–200 (2001).
   PubMedGoogle Scholar
• Dillon D, Zheng K, Negin B, Costa J. Detection of Ki-ras and p53 mutations by laser capture microdissection/PCR/SSCP. Methods Mol. Biol.293, 57–67 (2005).
   PubMedGoogle Scholar
• Tan YH, Liu Y, Eu KW et al. Detection of BRAFV600E mutation by pyrosequencing. Pathology40(3), 295–298 (2008).
   PubMed Web of Science ®Google Scholar
• Spittle C, Ward MR, Nathanson KL et al. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J. Mol. Diagn.9(4), 464–471 (2007).
   PubMed Web of Science ®Google Scholar
• Pinzani P, Santucci C, Mancini I et al.BRAFV600E detection in melanoma is highly improved by COLD-PCR. Clin. Chim. Acta412(11–12), 901–905 (2011).
   PubMed Web of Science ®Google Scholar
• Mancini I, Santucci C, Sestini R et al. The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. J. Mol. Diagn.12(5), 705–711 (2010).
   PubMed Web of Science ®Google Scholar
• Milbury CA, Li J, Liu P, Makrigiorgos GM. COLD-PCR: improving the sensitivity of molecular diagnostics assays. Expert Rev. Mol. Diagn.11(2), 159–169 (2011).
   PubMed Web of Science ®Google Scholar
• Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res.63(7), 1454–1457 (2003).
   PubMed Web of Science ®Google Scholar
• Pollock PM, Harper UL, Hansen KS et al. High frequency of BRAF mutations in nevi. Nat. Genet.33(1), 19–20 (2003).
   PubMed Web of Science ®Google Scholar
• Bauer J, Buttner P, Wiecker TS, Luther H, Garbe C. Risk factors of incident melanocytic nevi: a longitudinal study in a cohort of 1,232 young German children. Int. J. Cancer115(1), 121–126 (2005).
   PubMed Web of Science ®Google Scholar
• Maldonado JL, Fridlyand J, Patel H et al. Determinants of BRAF mutations in primary melanomas. J. Natl Cancer Inst.95(24), 1878–1890 (2003).
   PubMed Web of Science ®Google Scholar
• Yazdi AS, Palmedo G, Flaig MJ et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest. Dermatol.121(5), 1160–1162 (2003).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med.353(20), 2135–2147 (2005).
   PubMed Web of Science ®Google Scholar
• Lang J, Boxer M, Mackie R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum. Mutat.21(3), 327–330 (2003).
   PubMed Web of Science ®Google Scholar
• Meyer P, Klaes R, Schmitt C, Boettger MB, Garbe C. Exclusion of BRAFV599E as a melanoma susceptibility mutation. Int. J. Cancer106(1), 78–80 (2003).
   PubMedGoogle Scholar
• Edlundh-Rose E, Egyhazi S, Omholt K et al.NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res.16(6), 471–478 (2006).
   PubMed Web of Science ®Google Scholar
• Liu W, Kelly JW, Trivett M et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J. Invest. Dermatol.127(4), 900–905 (2007).
   PubMedGoogle Scholar
• Landi MT, Bauer J, Pfeiffer RM et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science313(5786), 521–522 (2006).
   PubMed Web of Science ®Google Scholar
• Bauer J, Buttner P, Murali R et al.BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res.24(2), 345–351 (2011).
   PubMed Web of Science ®Google Scholar
• Michaloglou C, Vredeveld LC, Soengas MS et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature436(7051), 720–724 (2005).
   PubMed Web of Science ®Google Scholar
• Dankort D, Curley DP, Cartlidge RA et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet.41(5), 544–552 (2009).
   PubMed Web of Science ®Google Scholar
• Kefford R, Arkenau H, Brown MP et al. Phase 1/2 study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase in patients with metastatic melanoma and other solid tumors. J. Clin. Oncol.28(15S) (2010) (Abstract 8503).
   Google Scholar
• Infante JR, Fecher LA, Nallapareddy S et al. Safety and efficacy results from the first-in-human study of the oral MEK1/2 nhibitor GSK112020212. J. Clin. Oncol.28(15 Suppl.), 2503 (2010).
   Web of Science ®Google Scholar
• Emery CM, Vijayendran KG, Zipser MC et al.MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA106(48), 20411–20416 (2009).
   PubMed Web of Science ®Google Scholar
• Montagut C, Sharma SV, Shioda T et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res.68(12), 4853–4861 (2008).
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature468(7326), 973–977 (2010).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell18(6), 683–695 (2010).
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAFV600E mutation. Sci. Signal3(149), ra84 (2010).
   PubMed Web of Science ®Google Scholar
• Little AS, Balmanno K, Sale MJ et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal4(166), ra17 (2011).
   PubMed Web of Science ®Google Scholar
• Kwong LN, Chin L. The brothers RAF. Cell140(2), 180–182 (2010).
   PubMedGoogle Scholar
• Poulikakos PI, Persaud Y, Janakiraman M et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature480(7377), 387–390 (2011).
   PubMed Web of Science ®Google Scholar
• Cohen Y, Xing M, Mambo E et al.BRAF mutation in papillary thyroid carcinoma. J. Natl Cancer Inst.95(8), 625–627 (2003).
   PubMed Web of Science ®Google Scholar
• Xing M, Vasko V, Tallini G et al.BRAF T1796A transversion mutation in various thyroid neoplasms. J. Clin. Endocrinol. Metab.89(3), 1365–1368 (2004).
   PubMedGoogle Scholar
• Nikiforova MN, Kimura ET, Gandhi M et al.BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab.88(11), 5399–5404 (2003).
   PubMed Web of Science ®Google Scholar
• Finkelstein ALG, Hui P, Prasad A et al. Papillary thyroid carcinomas with and without BRAFV600E mutations are morphologically distinct. Histopathology (2011) (In Press).
   Google Scholar
• Hishinuma A, Fukata S, Kakudo K, Murata Y, Ieiri T. High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. Thyroid15(9), 1079–1084 (2005).
   PubMedGoogle Scholar
• Ciampi R, Knauf JA, Kerler R et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest.115(1), 94–101 (2005).
   PubMed Web of Science ®Google Scholar
• Xing M, Westra WH, Tufano RP et al.BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab.90(12), 6373–6379 (2005).
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev.28(7), 742–762 (2007).
   PubMed Web of Science ®Google Scholar
• Namba H, Nakashima M, Hayashi T et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab.88(9), 4393–4397 (2003).
   PubMed Web of Science ®Google Scholar
• Bansal M, Nikiforow YE. B-Raf mutations in papillary thyroid carcinoma: diagnostic role, porgnostic implications, and a guide for clinical management. Path. Case Rev.15(4), 5 (2010).
   Google Scholar
• Leboeuf R, Baumgartner JE, Benezra M et al.BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J. Clin. Endocrinol. Metab.93(6), 2194–2201 (2008).
   PubMed Web of Science ®Google Scholar
• Vasko V, Hu S, Wu G et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J. Clin. Endocrinol. Metab.90(9), 5265–5269 (2005).
   PubMedGoogle Scholar
• Jo YS, Li S, Song JH et al. Influence of the BRAFV600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J. Clin. Endocrinol. Metab.91(9), 3667–3670 (2006).
   PubMed Web of Science ®Google Scholar
• Adeniran AJ, Hui P, Chhieng D, Prasad ML, Schofield K, Theoharis C. BRAF mutation testing of thyroid FNA specimens enhances predictability of malignancy in thyroid follicular lesions of undetermined significance. Acta Cytologica55(6), 570–575 (2011).
   PubMed Web of Science ®Google Scholar
• Greaves TS, Olvera M, Florentine BD et al. Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer90(6), 335–341 (2000).
   PubMed Web of Science ®Google Scholar
• Sclabas GM, Staerkel GA, Shapiro SE et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am. J. Surg.186(6), 702–709; discussion 709–710 (2003).
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. Metab.94(6), 2092–2098 (2009).
   PubMed Web of Science ®Google Scholar
• Rowe LR, Bentz BG, Bentz JS. Utility of BRAFV600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal3, 10 (2006).
   PubMedGoogle Scholar
• Jo YS, Huang S, Kim YJ et al. Diagnostic value of pyrosequencing for the BRAFV600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin. Endocrinol.70(1), 139–144 (2009).
   PubMed Web of Science ®Google Scholar
• Durante C, Puxeddu E, Ferretti E et al.BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab.92(7), 2840–2843 (2007).
   PubMed Web of Science ®Google Scholar
• Liu D, Liu Z, Condouris S, Xing M. BRAFV600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J. Clin. Endocrinol. Metab.92(6), 2264–2271 (2007).
   PubMed Web of Science ®Google Scholar
• Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br. J. Cancer96(1), 16–20 (2007).
   PubMed Web of Science ®Google Scholar
• Salerno P, De Falco V, Tamburrino A et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J. Clin. Endocrinol. Metab.95(1), 450–455 (2010).
   PubMed Web of Science ®Google Scholar
• Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch. Pathol. Lab Med.135(5), 569–577 (2011).
   PubMed Web of Science ®Google Scholar
• Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature418(6901), 934 (2002).
   PubMed Web of Science ®Google Scholar
• Lubomierski N, Plotz G, Wormek M et al.BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer104(5), 952–961 (2005).
   PubMed Web of Science ®Google Scholar
• Domingo E, Laiho P, Ollikainen M et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J. Med. Genet.41(9), 664–668 (2004).
   PubMed Web of Science ®Google Scholar
• Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv. Anat. Pathol.16(6), 405–417 (2009).
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Yanokura M, Banno K et al. Analysis of a correlation between the BRAFV600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. Int. J. Oncol.34(6), 1541–1547 (2009).
   PubMed Web of Science ®Google Scholar
• Bouzourene H, Hutter P, Losi L, Martin P, Benhattar J. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Fam. Cancer9(2), 167–172 (2010).
   PubMed Web of Science ®Google Scholar
• Hutchins G, Southward K, Handley K et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol.29(10), 1261–1270 (2011).
   PubMed Web of Science ®Google Scholar
• Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol.28(7), 1254–1261 (2010).
   PubMed Web of Science ®Google Scholar
• Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med.361(1), 98–99 (2009).
   PubMed Web of Science ®Google Scholar
• Richman SD, Seymour MT, Chambers P et al.KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J. Clin. Oncol.27(35), 5931–5937 (2009).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol.29(15), 2011–2019 (2011).
   PubMed Web of Science ®Google Scholar
• Lee JW, Yoo NJ, Soung YH et al.BRAF mutations in non-Hodgkin’s lymphoma. Br. J. Cancer89(10), 1958–1960 (2003).
   PubMed Web of Science ®Google Scholar
• Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res.62(23), 7001–7003 (2002).
   PubMed Web of Science ®Google Scholar
• Brose MS, Volpe P, Feldman M et al.BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res.62(23), 6997–7000 (2002).
   PubMed Web of Science ®Google Scholar
• Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv. Anat. Pathol.16(5), 267–282 (2009).
   PubMed Web of Science ®Google Scholar
• Wong KK, Tsang YT, Deavers MT et al.BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am. J. Pathol.177(4), 1611–1617 (2010).
   PubMed Web of Science ®Google Scholar
• Vereczkey I, Serester O, Dobos J et al. Molecular characterization of 103 ovarian serous and mucinous tumors. Pathol. Oncol. Res.17(3), 551–559 (2011).
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget2(4), 336–346 (2011).
   PubMed Web of Science ®Google Scholar
• Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol.8(7), 426–433 (2011).
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br. J. Cancer104(3), 392–398 (2011).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAFV600E mutation. N. Engl. J. Med.364(26), 2507–2516 (2011).
   PubMed Web of Science ®Google Scholar
• Loughrey MB, Waring PM, Tan A et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam. Cancer6(3), 301–310 (2007).
   PubMed Web of Science ®Google Scholar
• Kebebew E, Weng J, Bauer J et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg.246(3), 466–470; discussion 470–461 (2007).
   PubMed Web of Science ®Google Scholar
• Xing M, Clark D, Guan H et al.BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J. Clin. Oncol.27(18), 2977–2982 (2009).
   PubMed Web of Science ®Google Scholar
• Ball DW, Jin N, Rosen DM et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J. Clin. Endocrinol. Metab.92(12), 4712–4718 (2007).
   PubMed Web of Science ®Google Scholar
• Paik PK, Arcila ME, Fara M et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J. Clin. Oncol.29(15), 2046–2051 (2011).
   PubMed Web of Science ®Google Scholar
• Pratilas CA, Solit DB. Therapeutic strategies for targeting BRAF in human cancer. Rev. Recent Clin. Trials2(2), 121–134 (2007).
   PubMedGoogle Scholar
• Kim IJ, Park JH, Kang HC et al. Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum. Genet.114(1), 118–120 (2003).
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee JW, Soung YH et al.BRAF and KRAS mutations in stomach cancer. Oncogene22(44), 6942–6945 (2003).
   PubMed Web of Science ®Google Scholar
• Feng YZ, Shiozawa T, Miyamoto T et al.BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin. Cancer Res.11(17), 6133–6138 (2005).
   PubMed Web of Science ®Google Scholar
• Moreno -Bueno G, Sanchez-Estevez C, Palacios J, Hardisson D, Shiozawa T. Low frequency of BRAF mutations in endometrial and in cervical carcinomas. Clin. Cancer Res.12(12), 3865; author reply 3865–3866 (2006).
   PubMedGoogle Scholar
• Pappa KI, Choleza M, Markaki S et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol. Oncol.100(3), 596–600 (2006).
   PubMed Web of Science ®Google Scholar
• Yu J, Deshmukh H, Gutmann RJ et al. Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology73(19), 1526–1531 (2009).
   PubMedGoogle Scholar